HK1251574A1 - 四氫噁庚英吡啶化合物 - Google Patents

四氫噁庚英吡啶化合物

Info

Publication number
HK1251574A1
HK1251574A1 HK18111189.8A HK18111189A HK1251574A1 HK 1251574 A1 HK1251574 A1 HK 1251574A1 HK 18111189 A HK18111189 A HK 18111189A HK 1251574 A1 HK1251574 A1 HK 1251574A1
Authority
HK
Hong Kong
Prior art keywords
tetrahydrooxepinopyridine
compound
tetrahydrooxepinopyridine compound
Prior art date
Application number
HK18111189.8A
Other languages
English (en)
Inventor
小金丸陽平
宮本聰
永島信也
神川晃雄
米澤公一
小泉由佳
青木敏
荻山隆
川上晉平
國川茂輝
佐藤亮
肉倉淳一
柿元周一郎
山田博
玉置啓祐
Original Assignee
安斯泰來製藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安斯泰來製藥株式會社 filed Critical 安斯泰來製藥株式會社
Publication of HK1251574A1 publication Critical patent/HK1251574A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
HK18111189.8A 2015-08-19 2018-08-31 四氫噁庚英吡啶化合物 HK1251574A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015162320 2015-08-19

Publications (1)

Publication Number Publication Date
HK1251574A1 true HK1251574A1 (zh) 2019-02-01

Family

ID=58052257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111189.8A HK1251574A1 (zh) 2015-08-19 2018-08-31 四氫噁庚英吡啶化合物

Country Status (21)

Country Link
US (1) US9670219B2 (zh)
EP (1) EP3345909B1 (zh)
JP (1) JP6787320B2 (zh)
KR (1) KR102614279B1 (zh)
CN (1) CN107922426B (zh)
AR (1) AR105738A1 (zh)
AU (1) AU2016308406A1 (zh)
CA (1) CA2995554C (zh)
CO (1) CO2018002472A2 (zh)
EA (1) EA034794B1 (zh)
ES (1) ES2812246T3 (zh)
HK (1) HK1251574A1 (zh)
IL (1) IL257450A (zh)
MX (1) MX2018002118A (zh)
PH (1) PH12018500297A1 (zh)
PL (1) PL3345909T3 (zh)
PT (1) PT3345909T (zh)
SG (1) SG11201801193QA (zh)
TW (1) TW201722962A (zh)
WO (1) WO2017030171A1 (zh)
ZA (1) ZA201801098B (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020672A1 (en) * 2008-08-21 2010-02-25 Neurosearch A/S Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012113850A2 (en) 2011-02-25 2012-08-30 Janssen Pharmaceutica Nv (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
US20130005743A1 (en) * 2011-07-01 2013-01-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) * 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico

Also Published As

Publication number Publication date
WO2017030171A1 (ja) 2017-02-23
CN107922426B (zh) 2021-03-26
CN107922426A (zh) 2018-04-17
JP6787320B2 (ja) 2020-11-18
EP3345909A4 (en) 2019-04-10
US9670219B2 (en) 2017-06-06
KR102614279B1 (ko) 2023-12-18
EP3345909A1 (en) 2018-07-11
AU2016308406A1 (en) 2018-03-08
KR20180037983A (ko) 2018-04-13
TW201722962A (zh) 2017-07-01
CA2995554C (en) 2023-06-27
ZA201801098B (en) 2019-04-24
EA034794B1 (ru) 2020-03-23
BR112018003171A2 (pt) 2018-09-25
JPWO2017030171A1 (ja) 2018-06-07
CA2995554A1 (en) 2017-02-23
EP3345909B1 (en) 2020-06-17
EA201890514A1 (ru) 2018-07-31
MX2018002118A (es) 2018-06-18
US20170050973A1 (en) 2017-02-23
PL3345909T3 (pl) 2020-10-19
PT3345909T (pt) 2020-07-29
CO2018002472A2 (es) 2018-05-31
IL257450A (en) 2018-04-30
PH12018500297A1 (en) 2018-08-13
ES2812246T3 (es) 2021-03-16
AR105738A1 (es) 2017-11-01
SG11201801193QA (en) 2018-03-28

Similar Documents

Publication Publication Date Title
GB201510019D0 (en) Compounds
GB201514754D0 (en) Compounds
GB201514751D0 (en) Compounds
HK1255832A1 (zh) 吡喃並二吡啶化合物
GB201508747D0 (en) Compounds
GB201521524D0 (en) Compound
GB201518365D0 (en) Compounds
GB201520500D0 (en) Compounds
GB201520499D0 (en) Compounds
GB201508864D0 (en) Compounds
GB201510493D0 (en) Compounds
SG11201702781YA (en) Compounds
PT3331885T (pt) Compostos
GB201520419D0 (en) Compounds
GB201518950D0 (en) Compound
GB201508857D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201520391D0 (en) Compound
GB201520393D0 (en) Compound
GB201509303D0 (en) Compound
GB201521440D0 (en) Compounds
GB201521086D0 (en) Compounds
GB201519969D0 (en) Compounds